Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-30
2005-08-30
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266210, C544S284000, C544S287000
Reexamination Certificate
active
06936619
ABSTRACT:
Compounds of formula (I):or pharmaceutically acceptable salts or solvates thereof, whereinR1represents C1-4alkyl;R2represents halo, C1-4alkyl, C3-6cycloalkyl, C3-6cycloalkyloxy, —SO2(C1-4alkyl), optionally substituted C1-4alkyloxy, Het or —OHet;R3represents a bicyclic group of the formula wherein X and Y are selected from C and N, provided that at least one is C;Ring A together with X and Y represents a 5- or 6-membered aromatic ring containing 0, 1, 2 or 3 nitrogen atoms in the ring;n is), 1 or 2L represents a direct link, C1-4alkylene or C1-4alkoxyalkylene;R4represents H, —NR5R6, C3-6cycloalkyl, —OR7, Het1or Het4;R5and R6are independently selected from H, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkylene, —SO2(C1-4alkyl) and optionally substituted C1-4alkylR7is selected from H, C1-4alkyl, C1-4alkoxyalkyl, C3-6cycloalkyl, Het2and C1-4alkyl-Het3;R8is H or C1-4alkyl;Het, Het1, Het2and Het3independently represent an optionally substituted 4 to 7 membered saturated heterocyclic group which may be mono- or bi-cyclic and which contains one or more heteroatoms selected from N, O or S;Het4represents an optionally substituted 5 or 6 membered unsaturated heterocyclic group containing one or more heteroatoms selected from N, O or S;R9is H or C1-4alkyl;R10and R11are independently selected from H and C1-4alkyl;are useful in the treatment of hypertension, myocardial infarction, male erectile dysfunction (MED), hyperlipidaemia, cardiac arrhythmia, glaucoma and benign prostatic hyperplasia (BPH). They also find utility in the treatment of female sexual arousal dysfunction (FSAD).
REFERENCES:
patent: 4085213 (1978-04-01), Bindra
patent: WO 9723462 (1997-07-01), None
patent: WO 9830560 (1998-07-01), None
patent: WO 02053558 (2002-07-01), None
Blagg Julian
Fray Michael Jonathan
Lewis Mark Llewellyn
Mathias John Paul
Stefaniak Mark Henryk
Benson Gregg C.
Goddard Carl J.
Pfizer Inc.
Rao Deepak
Richardson Peter C.
LandOfFree
Quinazolinone compounds useful in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolinone compounds useful in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolinone compounds useful in therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3514180